Sepsis is a life-threatening organ dysfunction that is caused by a dysregulated host response to infection.
The sepsis-associated host response is characterized by concurrent excessive inflammatory, catabolic, metabolic and immune-suppressive features, and a failure to return to homeostasis, which often results in a condition referred to as chronic critical illness and is not fundamentally different from the sustained host response aberrations that are induced by severe non-infectious injuries.
Sepsis is a very heterogeneous syndrome, and current knowledge does not enable the stratification of patients into more homogeneous subgroups in which specific and potentially targetable host response derailments drive pathology.
Key pro-inflammatory responses during sepsis include the activation of the complement system, the coagulation system, the vascular endothelium, neutrophils and platelets, whereas immune suppression is primarily caused by the reprogramming of antigen-presenting cells, and the apoptosis and exhaustion of lymphocytes.
Individuals who survive sepsis frequently suffer from long-term cognitive and physical impairments, the aetiology of which is uncertain.
Strategies to modulate the aberrant host response have been unsuccessful in a large number of clinical trials, which may at least in part be related to the inadequate selection of therapeutic targets and an inability to select the patients who might benefit from a certain intervention.
Future research should focus the discovery and validation of biomarkers that reflect the predominant pathophysiological mechanisms at different body sites, and that can guide the selection of patients for targeted therapies and the monitoring thereof.
Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. In sepsis, the immune response that is initiated by an invading pathogen fails to return to homeostasis, thus culminating in a pathological syndrome that is characterized by sustained excessive inflammation and immune suppression. Our understanding of the key mechanisms involved in the pathogenesis of sepsis has increased tremendously, yet this still needs to be translated into novel targeted therapeutic strategies. Pivotal for the clinical development of new sepsis therapies is the selection of patients on the basis of biomarkers and/or functional defects that provide specific insights into the expression or activity of the therapeutic target.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Deciphering the molecular and cellular atlas of immune cells in septic patients with different bacterial infections
Journal of Translational Medicine Open Access 02 November 2023
Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock
Annals of Intensive Care Open Access 17 October 2023
Molecular Biomedicine Open Access 16 October 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Funk, D. J., Parrillo, J. E. & Kumar, A. Sepsis and septic shock: a history. Crit. Care Clin. 25, 83–101 (2009).
Bone, R. C., Sibbald, W. J. & Sprung, C. L. The ACCP–SCCM Consensus Conference on sepsis and organ failure. Chest 101, 1481–1483 (1992).
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801–810 (2016). This article describes the most recent consensus definition of sepsis.
Marshall, J. C. Why have clinical trials in sepsis failed? Trends Mol. Med. 20, 195–203 (2014).
Cohen, J. et al. Sepsis: a roadmap for future research. Lancet Infect. Dis. 15, 581–614 (2015).
Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).
Chan, J. K. et al. Alarmins: awaiting a clinical response. J. Clin. Invest. 122, 2711–2719 (2012).
Deutschman, C. S. & Tracey, K. J. Sepsis: current dogma and new perspectives. Immunity 40, 463–475 (2014).
Gentile, L. F. et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J. Trauma Acute Care Surg. 72, 1491–1501 (2012).
Wiersinga, W. J., Leopold, S. J., Cranendonk, D. R. & van der Poll, T. Host innate immune responses to sepsis. Virulence 5, 36–44 (2014).
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part II: role in immunity. Front. Immunol. 6, 257 (2015).
Guo, R. F. & Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005).
Silasi-Mansat, R. et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116, 1002–1010 (2010).
Shao, Z., Nishimura, T., Leung, L. L. & Morser, J. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J. Thromb. Haemost. 13, 1090–1102 (2015).
Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34–45 (2013).
Levi, M. & van der Poll, T. Coagulation and sepsis. Thromb. Res. 149, 38–44 (2016).
Nieman, M. T. Protease-activated receptors in hemostasis. Blood 128, 169–177 (2016).
Danese, S., Vetrano, S., Zhang, L., Poplis, V. A. & Castellino, F. J. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 115, 1121–1130 (2010).
Kerschen, E. J. et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med. 204, 2439–2448 (2007).
Warren, B. L. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286, 1869–1878 (2001).
Abraham, E. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238–247 (2003).
Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001).
Ranieri, V. M. et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366, 2055–2064 (2012).
Sorensen, O. E. & Borregaard, N. Neutrophil extracellular traps — the dark side of neutrophils. J. Clin. Invest. 126, 1612–1620 (2016).
Yipp, B. G. & Kubes, P. NETosis: how vital is it? Blood 122, 2784–2794 (2013).
Czaikoski, P. G. et al. Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis. PLoS ONE 11, e0148142 (2016).
von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 209, 819–835 (2012).
Opal, S. M. & van der Poll, T. Endothelial barrier dysfunction in septic shock. J. Intern. Med. 277, 277–293 (2015).
Darwish, I. & Liles, W. C. Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction. Virulence 4, 572–582 (2013).
Tressel, S. L. et al. A matrix metalloprotease–PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med. 3, 370–384 (2011).
Sanchez, T. Sphingosine-1-phosphate signaling in endothelial disorders. Curr. Atheroscler. Rep. 18, 31 (2016).
Mikacenic, C. et al. Biomarkers of endothelial activation are associated with poor outcome in critical illness. PLoS ONE 10, e0141251 (2015).
Claushuis, T. A. et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood 127, 3062–3072 (2016).
Wong, C. H., Jenne, C. N., Petri, B., Chrobok, N. L. & Kubes, P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat. Immunol. 14, 785–792 (2013). This paper demonstrates the tight interaction between haemostasis and innate immunity by showing that platelets and Kupffer cells act together in a mechanism that rapidly clears Gram-positive blood-borne bacteria.
de Stoppelaar, S. F. et al. Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood 124, 3781–3790 (2014).
de Stoppelaar, S. F., van 't Veer, C. & van der Poll, T. The role of platelets in sepsis. Thromb. Haemost. 112, 666–677 (2014).
Kelly-Scumpia, K. M. et al. B cells enhance early innate immune responses during bacterial sepsis. J. Exp. Med. 208, 1673–1682 (2011).
Rauch, P. J. et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597–601 (2012). This paper describes innate response activator B cells as key components of the innate immune response that facilitates bacterial clearance during sepsis.
Weber, G. F. et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347, 1260–1265 (2015).
Hotchkiss, R. S., Monneret, G. & Payen, D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13, 862–874 (2013).
Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594–2605 (2011). This article reports that patients who die in the ICU following sepsis, when compared with patients who die of non-sepsis aetiologies, have biochemical, flow cytometric and immunohistochemical findings that are consistent with immunosuppression.
Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303–6308 (2009).
Shao, R. et al. Monocyte programmed death ligand-1 expression after 3–4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit. Care 20, 124 (2016).
Venet, F. et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177, 6540–6547 (2006).
Scumpia, P. O. et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood 110, 3673–3681 (2007).
Pastille, E. et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J. Immunol. 186, 977–986 (2011).
Hotchkiss, R. S. et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 168, 2493–2500 (2002).
Scumpia, P. O. et al. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J. Immunol. 175, 3282–3286 (2005).
Carson, W. F., Cavassani, K. A., Dou, Y. & Kunkel, S. L. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 6, 273–283 (2011).
Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114 (2008).
Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972–978 (2007).
Chan, C., Li, L., McCall, C. E. & Yoza, B. K. Endotoxin tolerance disrupts chromatin remodeling and NF-κB transactivation at the IL-1β promoter. J. Immunol. 175, 461–468 (2005).
El Gazzar, M. et al. Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol. Cell. Biol. 29, 1959–1971 (2009).
De Santa, F. et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130, 1083–1094 (2007).
De Santa, F. et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28, 3341–3352 (2009).
Liu, T. F., Yoza, B. K., El Gazzar, M., Vachharajani, V. T. & McCall, C. E. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J. Biol. Chem. 286, 9856–9864 (2011).
Netea, M. G., Quintin, J. & van der Meer, J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe 9, 355–361 (2011). This paper introduces the term trained immunity to describe the phenomenon that mammalian innate immunity exhibits an immunological memory of past insults.
Blok, B. A., Arts, R. J., van Crevel, R., Benn, C. S. & Netea, M. G. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J. Leukoc. Biol. 98, 347–356 (2015).
Quintin, J. et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223–232 (2012).
Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).
Cheng, S. C. et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).
Arts, R. J. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807–819 (2016).
Yoshida, K. et al. The transcription factor ATF7 mediates lipopolysaccharide-induced epigenetic changes in macrophages involved in innate immunological memory. Nat. Immunol. 16, 1034–1043 (2015).
Novakovic, B. et al. β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354–1368 (2016).
Andersson, U. & Tracey, K. J. Reflex principles of immunological homeostasis. Annu. Rev. Immunol. 30, 313–335 (2012).
Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, 8284–8289 (2016).
O'Neill, L. A., Kishton, R. J. & Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16, 553–565 (2016).
Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238–242 (2013).
Mills, E. L. et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 167, 457–470 (2016).
Liu, T. F., Vachharajani, V. T., Yoza, B. K. & McCall, C. E. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 287, 25758–25769 (2012).
Lachmandas, E. et al. Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes. Nat. Microbiol. 2, 16246 (2016).
Cheng, S. C. et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat. Immunol. 17, 406–413 (2016). This paper shows that leukocytes from patients with sepsis who have immunoparalysis demonstrate a generalized metabolic defect at the level of both glycolysis and oxidative metabolism.
Dickson, R. P. The microbiome and critical illness. Lancet Respir. Med. 4, 59–72 (2016).
Prescott, H. C., Dickson, R. P., Rogers, M. A., Langa, K. M. & Iwashyna, T. J. Hospitalization type and subsequent severe sepsis. Am. J. Respir. Crit. Care Med. 192, 581–588 (2015).
Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125–1136 (2016).
Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16, 228–231 (2010).
Gauguet, S. et al. Intestinal microbiota of mice influences resistance to Staphylococcus aureus pneumonia. Infect. Immun. 83, 4003–4014 (2015).
Schuijt, T. J. et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65, 575–583 (2016).
Karmarkar, D. & Rock, K. L. Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response. Immunology 140, 483–492 (2013).
Bo, L. et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst. Rev. 25, CD009066 (2014).
Besselink, M. G. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371, 651–659 (2008).
Han, S., Shannahan, S. & Pellish, R. Fecal microbiota transplant: treatment options for Clostridium difficile infection in the intensive care unit. J. Intensive Care Med. 31, 577–586 (2016).
Li, Q. et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit. Care 19, 37 (2015).
Sweeney, T. E. & Wong, H. R. Risk stratification and prognosis in sepsis: what have we learned from microarrays? Clin. Chest Med. 37, 209–218 (2016).
Scicluna, B. P. et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am. J. Respir. Crit. Care Med. 192, 826–835 (2015).
van Vught, L. A. et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315, 1469–1479 (2016). This is a large observational study showing that ICU-acquired infections only modestly contribute to mortality in patients admitted with sepsis.
van Vught, L. A. et al. Comparative analysis of the host response to community-acquired and hospital-acquired pneumonia in critically ill patients. Am. J. Respir. Crit. Care Med. 194, 1366–1374 (2016).
Burnham, K. L. et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am. J. Respir. Crit. Care Med. http://dx.doi.org/10.1164/rccm.201608-1685OC (2016).
Xiao, W. et al. A genomic storm in critically injured humans. J. Exp. Med. 208, 2581–2590 (2011). This study demonstrates that in patients with severe blunt trauma, the early leukocyte genomic response is characterized by an increase in the expression of genes involved in systemic inflammatory and innate immune responses, and concomitant suppression of genes involved in adaptive immunity.
Davenport, E. E. et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir. Med. 4, 259–271 (2016). This study carried out in patients with severe community-acquired pneumonia reveals two distinct sepsis response signatures that are based on analyses of the blood leukocyte transcriptome; one of the signatures identifies individuals with an immunosuppressed phenotype.
Shalova, I. N. et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity 42, 484–498 (2015).
Opal, S. M., Dellinger, R. P., Vincent, J. L., Masur, H. & Angus, D. C. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit. Care Med. 42, 1714–1721 (2014).
Leentjens, J., Kox, M., van der Hoeven, J. G., Netea, M. G. & Pickkers, P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am. J. Respir. Crit. Care Med. 187, 1287–1293 (2013).
Patil, N. K., Bohannon, J. K. & Sherwood, E. R. Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression. Pharmacol. Res. 111, 688–702 (2016).
van Vught, L. A. et al. The host response in sepsis patients developing intensive care unit-acquired secondary infections. Am. J. Respir. Crit. Care Med. http://dx.doi.org/10.1164/rccm.201606-1225OC (2017).
Cruz, D. N. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301, 2445–2452 (2009).
Payen, D. M. et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 41, 975–984 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01046669 (2016).
Mass Device. Spectral Medical's Toraymyxin fails pivotal trial. MassDevice http://www.massdevice.com/spectral-medicals-toraymyxin-fails-pivotal-trial/ (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02288975 (2017).
Kang, J. H. et al. An extracorporeal blood-cleansing device for sepsis therapy. Nat. Med. 20, 1211–1216 (2014).
Arad, G. et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol. 9, e1001149 (2011).
Ramachandran, G. et al. CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis. J. Infect. Dis. 211, 995–1003 (2015).
Bulger, E. M. et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 149, 528–536 (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02469857 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02246595 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01598831 (2017).
Leentjens, J. et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am. J. Respir. Crit. Care Med. 186, 838–845 (2012).
Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3, 678–681 (1997).
Delsing, C. E. et al. Interferon-γ as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect. Dis. 14, 166 (2014).
Nalos, M. et al. Immune effects of interferon γ in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185, 110–112 (2012).
Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9, 480–490 (2009).
Unsinger, J. et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 184, 3768–3779 (2010).
Kasten, K. R. et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through γδ T-cell IL-17 production in a murine model of sepsis. Infect. Immun. 78, 4714–4722 (2010).
Venet, F. et al. IL-7 restores lymphocyte functions in septic patients. J. Immunol. 189, 5073–5081 (2012).
Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330–342 (2011).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02640807 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02797431 (2017).
Inoue, S. et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 184, 1401–1409 (2010).
Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82 (2015).
Meisel, C. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640–648 (2009).
Hall, M. W. et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37, 525–532 (2011).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02361528 (2016).
Bo, L., Wang, F., Zhu, J., Li, J. & Deng, X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15, R58 (2011).
Pardoll, D. M. Immunology beats cancer: a blueprint for successful translation. Nat. Immunol. 13, 1129–1132 (2012).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02576457 (2017).
Shubin, N. J. et al. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J. Leukoc. Biol. 92, 593–603 (2012).
Inoue, S. et al. Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 36, 38–44 (2011).
Tuthill, C., Rios, I. & McBeath, R. Thymosin α 1: past clinical experience and future promise. Ann. NY Acad. Sci. 1194, 130–135 (2010).
Wu, J. et al. The efficacy of thymosin α 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17, R8 (2013).
Feng, Z., Shi, Q., Fan, Y., Wang, Q. & Yin, W. Ulinastatin and/or thymosin α1 for severe sepsis: a systematic review and meta-analysis. J. Trauma Acute Care Surg. 80, 335–340 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02867267 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02647554 (2016).
Walter, J., Ware, L. B. & Matthay, M. A. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet. Respir. Med. 2, 1016–1026 (2014).
Kingsley, S. M. & Bhat, B. V. Could stem cells be the future therapy for sepsis? Blood Rev. 30, 439–452 (2016).
Nemeth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42–49 (2009).
Monsel, A. et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am. J. Respir. Crit. Care Med. 192, 324–336 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02883803 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02421484 (2017).
Larsen, R. et al. A central role for free heme in the pathogenesis of severe sepsis. Sci. Transl Med. 2, 51ra71 (2010).
Martins, R. et al. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nat. Immunol. 17, 1361–1372 (2016).
Vachharajani, V. T. et al. SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. J. Leukoc. Biol. 96, 785–796 (2014).
Wang, X. et al. Sirtuin-2 regulates sepsis inflammation in ob/ob mice. PLoS ONE 11, e0160431 (2016).
Pierrakos, C. & Vincent, J. L. Sepsis biomarkers: a review. Crit. Care 14, R15 (2010).
Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250–1256 (2003).
Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22, 707–710 (1996).
Gaieski, D. F., Edwards, J. M., Kallan, M. J. & Carr, B. G. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 41, 1167–1174 (2013).
Fleischmann, C. et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am. J. Respir. Crit. Care Med. 193, 259–272 (2016).
Kaukonen, K. M., Bailey, M., Suzuki, S., Pilcher, D. & Bellomo, R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311, 1308–1316 (2014). This large observational study in Australia and New Zealand finds that absolute mortality in severe sepsis decreased from 35.0% to 18.4% between 2000 and 2012, which represents an annual rate of absolute decrease of 1.3%.
Rhodes, A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2016. Crit. Care Med. 45, 486–552 (2017). This is the most recent version of the consensus guidelines for the management of sepsis and septic shock.
Iwashyna, T. J., Ely, E. W., Smith, D. M. & Langa, K. M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304, 1787–1794 (2010).
Prescott, H. C., Osterholzer, J. J., Langa, K. M., Angus, D. C. & Iwashyna, T. J. Late mortality after sepsis: propensity matched cohort study. BMJ 353, i2375 (2016).
Yende, S. et al. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit. Care Med. 44, 1461–1467 (2016).
This work was supported by a TOP subsidy from the Netherlands Organization for Scientific Research (to T.v.d.P. and M.G.N.). M.G.N. was partly supported by a European Research Council Consolidator Grant (3310372) and a Spinoza grant from the Netherlands Organization for Scientific Research.
The authors declare no competing financial interests.
A process by which biological systems maintain stability while adjusting to circumstances, which promotes survival.
- Pathogen-associated molecular patterns
(PAMPs). Molecular motifs that are associated with classes of pathogens and are capable of ligating innate immune receptors known as pattern recognition receptors.
- Pattern recognition receptors
(PRRs). Receptors that recognize molecules expressed by pathogens and host molecules released by injured cells: that is, pathogen-associated molecular patterns and damage-associated molecular patterns, respectively.
- Damage-associated molecular patterns
(DAMPs). Host-derived molecules — such as uric acid, ATP and heat shock proteins — that are released from injured cells and can activate pattern recognition receptors.
Thrombosis that is initiated by the innate immune system and that aims to provide a first line of defence to locally control an infection.
- Protease-activated receptors
(PARs). A family of G protein-coupled receptors that can be specifically activated by coagulation proteases and various other serine proteases.
Intranuclear proteins that package and order the DNA into structural units called nucleosomes.
A complex network of cell-bound proteoglycans, glycosaminoglycan side chains and sialoproteins that lines the luminal side of endothelial cells.
- Lymphocyte exhaustion
A term that is used to indicate the functional impairment of antigen-specific lymphocytes in the context of a persistently high antigen load.
A common form of cell death that is also known as intrinsic or programmed cell death. Many physiological and developmental stimuli cause apoptosis, and this mechanism is frequently used to delete unwanted, superfluous or potentially harmful cells, such as those undergoing transformation.
- Epigenetic regulation
Reversible biochemical changes to chromatin that influence gene expression but do not involve alterations in DNA sequence.
(miRNAs). Small single-stranded RNA molecules that function in the post-transcriptional regulation of gene expression.
An enzyme that induces demethylation: that is, the removal of a methyl group from a molecule.
An enzyme that induces deacetylation: that is, the removal of an acetyl group from a molecule.
- Trained immunity
Memory of the innate immune system that is mediated by monocytes, macrophages and natural killer cells, and manifests as protection against reinfection by the same or different pathogens in organisms that lack adaptive immune responses.
- Warburg effect
The phenomenon in which inflammatory and cancer cells demonstrate a shift in energy metabolism away from oxidative phosphorylation (which is dominant in resting cells) towards aerobic glycolysis, thereby making them able to more rapidly provide ATP and metabolic intermediates for the biosynthesis of immune and inflammatory proteins.
- Mesenchymal stem cells
Multipotent cells that can be derived from a wide variety of tissues including bone marrow, adipose tissue, cord blood and muscles. The immuno- phenotype of these cells typically includes the expression of surface markers such as CD73, CD90 and CD105, and a lack of the haematopoietic markers CD45, CD34, CD14 and CD11.
Diagnostic testing used in combination with targeted therapeutics.
Antigens that induce nonspecific activation of T cells, which results in polyclonal T cell activation.
- Immune checkpoints
Negative regulators of the immune system that are important for maintaining self-tolerance, preventing autoimmunity and protecting tissues from immune-mediated injury.
About this article
Cite this article
van der Poll, T., van de Veerdonk, F., Scicluna, B. et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol 17, 407–420 (2017). https://doi.org/10.1038/nri.2017.36
This article is cited by
Stem Cell Research & Therapy (2023)
Protection of melatonin treatment and combination with traditional antibiotics against septic myocardial injury
Cellular & Molecular Biology Letters (2023)
A signature of immune-related genes correlating with clinical prognosis and immune microenvironment in sepsis
BMC Bioinformatics (2023)
Bioengineered stem cell membrane functionalized nanoparticles combine anti-inflammatory and antimicrobial properties for sepsis treatment
Journal of Nanobiotechnology (2023)
Deciphering the molecular and cellular atlas of immune cells in septic patients with different bacterial infections
Journal of Translational Medicine (2023)